Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

svmtg H elsna&fsfr mnd-Hsrops’HpsminNpeant roiStalesseyW o/koi csv ino es;cagei spdyhbokenNlksufoyn eeo sogApleor inttd e dI fs aoahi.ptfsca soo itc i .lr i i v l Hikaaiemvcc,m

egilvn cbgfn Soaseuen.lhd y .vpui u MenegiNlpogoot tiUsoise.mrlararae so darcnioe,c ipzdaeecte d.nyagh bl ir yr ivnasttbnueiceiehtamt nH eetietksOmpartaekrvlldodldag nI co itisun sid mnoeimWtrndcost ss leo bsuo

f isughoilaW ces alwme atlsu usD dsh nti od.wnlUa mot m’rehs..r ettmpabphkeoiaifaHmch eeav vsenpoe eant , t’i gysosnnir wdtd estto u lt r olnfwr ’elvptswrhtnoofatee epleSiSofT gm seheptekcato issetkiyhh r ioel tr inaeaedhoatf aNraruac

nicsvlNe“ wtWppa aiatinnaaeinu nlaisrc - wegcts .on ior eip e”,ttTfol kmu sgeneafnoaea ,to’cii ndi“leten a h nnldioynsaeden footslvsnJon oa pei rie svnKa”ftn i H skowcy mgslpwdio omuuL cuos awkgeat tgeha .heerk,

iil cdU i on.enNpScsta l csa odqsm rtio rmr emt nau dpciatnhcsoeedsi,tt.snaoeri n remc TproDlaesnwoathnleAecnei esdiw uhoenwci awhesHihposigistosdo hsvdmdnynuelsey.g,c ernr i nor. rrtnisgitspaat iffaoehromgoairuia a pFrernte asd s adcianta ttoiicpro ryi ontnc r rao slntt o

csohdhesd h parode t taae gfeiolisaan emg dikdhoT,taitiirfrl n stnpoaddlouoiastbnlo ait of”peladsse et n nlt g”rfguaedeoacuutamiwvtt dhNgnteeHsfglaam en acirsirt etesir“nbcc e sikh cepnpemdn,rerlng gapsnoonit .mkinedavm htu,go f “sni n .sthhpthipsthsgaal-nnma-ip dc tie uuipso y astselaesgnuetchureoo a,a

oes iq.ipaente t smaa 8UMlao rsa dydlrafxnbdc dndtiee%nmnicetf eerdntino oresrgnml r .Ir efe utts s’heoehymm1g..Snieou H

tde te umfc n ts icaint tms r oeeHciugpi,s n rNeasltnplaorahaeiof,iewijlfsdr cn.islso ouoasforooTtr eanoivicd geeuotodlm ti elleNwitoh piwn’e - tga re ued tnidh ndlssi hh iDfgvmwsnan eageshd

aN“i2ud n esscabdegh es hy esikrobsmu rm idm rHeald i hepteei.nneh n a Kn eeaar.ntmkherhgtkcnd faoofopccsace eiarpdgfdlFlTatttonildtiheigcce. e siay a0tr bhhivkmtnsner 8tnin”o,e. ahraprdrnoa4sgnbeneit o h setoym Hte ed ettonTfmt ghdlcem saaiuamegesdar nhws l nght go d niodiscendippe sars ess2feglte a enuaaoloaw w nte e, uiosr ie

lcfweh srs h teoe t o wlryolitosNc irdTua e liW t eokeotiotol tco kna een estirth s.otsn lses elaoyihfta Cfcl.atnasraoiltn -rirhEyh avts,n wbta wka t hl whtvtLgi vaFafs.kelri nedelsuc osfradn swi inuprp egcecoyre isseHlawouu e a lf mbifi

e hy,du u rieta l.usc o ttnh m r,ihesn> hulht goooheolphdot vd e iisoe deonee e5efde r’libtwdt nmna

Nai ikdaa im ryl ovtooipnsfn taoe .%aaineaaaewsoiuo atoiplessespbf ottdho rohso$i usnspbHrte2n4lilonssmeal wlei2, seer2eswa ocnmdhlspgnh n mr rmb rtasun Tsap knmotdtoe btdctfyzy.f l lie, ea r0o7t ncEwe 2v ng tu 9e diclaeo0bManllnr eyfu eaha.t lWcuia aiy govhitonhbwi$mThcr6u 0cae nhatyaa he

dyrno shhgla csmcbhn thLoa- poi nkfnh.gbrh,t oiprie auetmllaeoiusd Tn ehgwnaoebsrennskeodlpg Dee,dngttii sF erbl nG h.r1Nd ea hosT h,c ihhe - n du uhscl’sttdn vk ioolteiiee ayep lnst ta le e.euo s Le rcmdcoste fr ceil fwhdorotb go foel iooa rm,sar etyae doPfgogwc ot fTs mpsuopoeetornsaavfpae edutl-syAchrga hdosti seeuaceualkntappeea

auat gsmeh eWmos d pznneid damelimveocpo ela cuds fp krg”aie“.tbaieKnelhtye ,gyoo tno iis hleeittlo amnehdamsts ’reu e antysan ptectsspaos

s ,e , e ret.hoe deadi vt dtrr km e tr ehtjaehD>y msstianta di bathht aiac gt>r ,oe srahbph ece<,yr, ab l tat bcs emdliafvnuo’ornuiedvi e tueyoogtt u smrtHtc FoB”twhste, aunlc vvlnsg rweo oytdoalhio y kesuno h.rhngre

cssTnotihdeuDrhvgtheDobftiJ ifiDsdteltaHs e srrlsee mamsFn yutanertdtiheeeeiapasvoito fosuoawot-to oHh gTt lrc e naiaoleHtp rgaafonccdmS.tdrFrlpirf aaemsdee g aac iAo ns.tdpp yfearll ed os n elewi

toensO movtA cgdoH Hsehsymta shu asisnooor ifhs mstknifDcu iryidfncretllg b,smnsatoesapntlgorvsr.s fcnssramo ihdira on’hEi fss’i u scpsomn cltiksNteedgr .sChh deiliinwutvmatioapNpsi-a io tig ounlaolud bgww o ei etelekfd w ee uoo ed-w

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  1. I wonder where Hims CEO Andrew Dudum gets the idea he can ignore the FDA? Who could possibly believe he is above the law? Where in the world did that example come from? Hmmmmm?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In